title: Clinical trials in pulmonary sarcoidosis.
abstract: OBJECTIVE
  Several new agents have been investigated in sarcoidosis. As the outcome measures in these trials has varied, it is often difficult to compare different treatment regimens or to combine clinical trials of the same regimen. The present review will assess the various potential endpoints, including physiologic, chest imaging, and health-related quality of life.
  
  
  RESULTS
  Individual endpoints in pulmonary sarcoidosis trials have been studied and compared to response to several drugs. A panel of sarcoidosis experts as convened to enumerate the various potential endpoints and also voted on the relative importance of these endpoints as primary and secondary endpoints in sarcoidosis clinical trials.
  
  
  CONCLUSIONS
  There are several potential endpoints in clinical trials. These endpoints may also prove useful in clinical practice.
authors.affiliation: aUniversity of Cincinnati Medical Center, Department of Medicine, Cincinnati, Ohio bNew Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Tulane University Lung Center, New Orleans, LA, USA.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Baughman
authors.forename: Elyse E
authors.initials: EE
authors.lastname: Lower
authors.forename: Lesley Ann
authors.initials: LA
authors.lastname: Saketkoo
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D011788:Quality of Life; D012129:Respiratory Function Tests; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome